Unusual adult-onset manifestation of an attenuated Bartter's syndrome type IV renal phenotype caused by a mutation in BSND Sir, Bartter's syndrome (BS) comprises a range of overlapping autosomal recessive renal salt-losing phenotypes, characterized by hypocalaemic metabolic alkalosis. The antenatal BS variant associated with sensorineural deafness (BS type IV) is caused by mutations in BSND [1] . This gene encodes barttin, an essential b-subunit for ClC-Ka and ClC-Kb chloride channels in basolateral membranes of renal tubular epithelia and inner ear [2] . BS type IV presents with life-threatening neonatal volume depletion accompanied by hypocalaemia [3, 4] . Chronic renal failure frequently develops during infancy [1, 3] , although this finding is not uniformly reported [4] , but persistent hypercalciuria and nephrocalcinosis are unusual findings.
Herein we report a deaf daughter of consanguineous parents, who was referred to our nephrology unit for the first time at the age of 20, because of refractory hypocalaemia. The patient was born by vaginal delivery, and although the mother had a large amount of amniotic fluid on ultrasound examination during pregnancy, the post-natal period was unremarkable until the 2nd year of life, when parents reported hearing loss and she was diagnosed with congenital bilateral sensorineural deafness. Thereafter the clinical history was unexceptional apart from poly dipsia and polyuria. The patient's height and weight reached, respectively, 165 cm (percentile range of 25-50) and 70 kg (percentile range of 50-75). Serum and urine biochemical data at admission are summarized in Table 1 . The association of hypocalaemic metabolic alkalosis and hearing impairment led us to consider the diagnosis of BS type IV. Plasma renin and aldosterone were abnormally high and subsequent evaluation detected hypercalciuria and nephrocalcinosis ( Figure 1A ). The patient was found to be homozygous for the BSND c.139G>A allele ( Figure 1B) , resulting in Gly to Arg at position 47 (p.G47R). The patient was prescribed 40 mEq/day of chloride potassium and 25 mg/day of spironolactone. Three months after diagnosis, serum potassium and creatinine were 3.5 mmol/l and 61.9 mmol/l, respectively. However, hypercalciuria persisted.
A late-onset presentation of a renal phenotype in BS type IV has been previously published [5] . Similar to our case, the patient was homozygous for the p.G47R allele, but a decreased glomerular filtration rate (GFR) and unexplained bilateral nephrocalcinosis, given the absence of hypercalciuria, were reported. The same mutation was also described, in homozygosity, in two additional Spanish kindreds, with affected individuals presenting polyhydramnios, premature birth and salt loss, although not as severe as usually reported for BS type IV [6] . Since the co-expression of p.G47R barttin and ClC-Ka resulted in a Cl À current reduction to the same extent as those observed for other missense mutations [2], we can hypothesize that this allele enables barttin to retain some residual function with ClC-Kb, therefore conditioning a milder phenotype. In addition, the better long-term GFR preservation possibly allows for the filtered calcium to be over-excreted leading to more persistent hypercalciuria, as demonstrated for the first time in our patient. Here, we report on a patient with a NSCLC, who developed ESRD after two cycles of chemotherapy with a gemcitabine/platinum combination. Because of the good performance status of the patient and the chemo-sensitivity of the tumour, treatment was completed with DXL 65 mg/m 2 and carboplatin 200 mg/m 2 on day 1 and day 21 with sequential radiotherapy. DXL was infused over 1 h, followed by carboplatin infusion over 1 h. HD was immediately performed after the end of carboplatin application. Total plasma concentrations of DXL were evaluated in the blood samples collected 1,3 and 5 h after the end of the DXL infusion, using solid phase extraction and high-performance liquid chromatography. Pharmacokinetic analysis of DXL revealed a rapid decrease of plasma concentrations immediately after administration. Only very low amounts of DXL-comparable with plasma concentrations of patients without renal failure-were detected 1 h after the end of the infusion of 65 mg/m 2 DXL (Figure 1 ), suggesting that DXL is rapidly bound to plasma proteins as described before [4] . DXL was not dialysed, since increased concentrations were found in plasma samples collected from the venous line compared with samples collected from the arterial line ( Figure 1A) . Interestingly, even lower amounts of DXL in the blood were found after the second cycle of 
